Follow-On Biologics Under Eshoo’s Bill Not A “Viable Business,” Sandoz Says
Executive Summary
No pharmaceutical company will develop follow-on biologics if anything close to the brand-friendly legislation introduced by Rep. Anna Eshoo, D-Calif., to create a regulatory pathway is passed by Congress, Sandoz Biopharmaceuticals head Hannes Teissl said
You may also be interested in...
Follow-on Biologics: As Mark-Ups Loom, What's Waxman's End Game?
Coming to an abrupt halt after racing at full speed is never easy, but that seems to be the best play available to generic advocates of a legislative pathway for follow-on biologics
Follow-on Biologics: As Mark-Ups Loom, What's Waxman's End Game?
Coming to an abrupt halt after racing at full speed is never easy, but that seems to be the best play available to generic advocates of a legislative pathway for follow-on biologics
Biosimilar Interchangeability Does Not Create Substitution Under House Bills
While biosimilars legislation is seen as a means of lowering health care costs, interchangeability provisions in House bills creating a biosimilars approval pathway would not be enough to allow automatic substitution at the pharmacy level - the route to the highest savings